The FDA agreed on key elements of the proposed Phase 3 trial design, including the study population and dosing regimen, following ATH434’s demonstration of a 48% slowing of disease progression ...
Source LinkThe FDA agreed on key elements of the proposed Phase 3 trial design, including the study population and dosing regimen, following ATH434’s demonstration of a 48% slowing of disease progression ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.